Opthea Limited Overview
Pro stress-test →Opthea is a clinical-stage biopharmaceutical company developing drugs for eye diseases, with its lead product sozinibercept (OPT-302) in Phase 3 trials designed to inhibit VEGF-C and VEGF-D to treat wet age-related macular degeneration and diabetic macular edema. The company targets a large patient population in a therapeutic area with significant unmet medical needs.
Strategic Profile
Pro stress-test →The company recently experienced a significant setback when its Phase 3 COAST and ShORe trials for sozinibercept failed to meet primary endpoints, leading to major restructuring including management changes, 80%+ workforce reduction, a settlement with DFA Investors via USD20M payment and 9.99% equity issuance, leaving approximately USD20M in cash. Opthea now faces strategic uncertainty with new leadership and a planned six-month strategic review.
Competitive Landscape
Pro stress-test →Opthea competes in the wet AMD and DME treatment space dominated by established players administering anti-VEGF-A therapies. Wet AMD affects approximately 3.5 million people in the US and Europe, with many patients not achieving optimal vision outcomes with current anti-VEGF-A therapies. However, Opthea's failed Phase 3 trials have significantly weakened its competitive position.
Industry Context
Opthea Limited operates in Biopharmaceuticals - Ophthalmology/Retinal Diseases.
Key facts
Founded: 2015 · Headquarters: Melbourne, Australia · Employees: Significantly reduced post-restructuring · Revenue: $0.146M (2025) · Market cap: $0.82B AUD